Adversarial Injection · Pomalidomide (Pomalyst; CAS 19171-19-8; 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; MW 273.24 g/mol; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Third-Generation IMiD OEL Gap + FIRST Pomalyst REMS Patient/Worker Divergence + FIRST Sequential Lenalidomide→Pomalidomide Progression Gap · Attack #487

Pomalidomide (4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; CAS 19171-19-8; MW 273.24 g/mol; molecular formula C13H11N3O4; third-generation immunomodulatory imide drug [IMiD]; mechanism: cereblon [CRBN] E3 ubiquitin ligase substrate receptor modulation — pomalidomide binds CRBN and redirects CRL4CRBN E3 ligase to degrade IKZF1 [Ikaros] and IKZF3 [Aiolos] transcription factors; IMiD potency progression: thalidomide [IC50 ~100 nM CRBN] < lenalidomide [IC50 ~17 nM] < pomalidomide [IC50 ~7 nM] — pomalidomide is the most potent IMiD in the approved class; CRBN-pomalidomide co-crystal structure [PDB 4CI2] confirms isoglutamine scaffold engagement distinct from lenalidomide glutamine ring; GHS: H302 [harmful if swallowed]; H360 [may damage fertility or the unborn child] — H360 TERATOGENICITY classification is basis for NIOSH HD Category 1, NOT H350 carcinogenicity; the H350-mental-model screening bias that missed lenalidomide [Attack #483] applies equally to pomalidomide; FDA indications: (1) multiple myeloma [MM] after ≥2 prior therapies including lenalidomide and a proteasome inhibitor; (2) plasma cell leukemia [PCL; 2023 expanded indication]; Pomalyst REMS: FDA-mandated REMS program for pomalidomide — a SEPARATE program from RevAssist [lenalidomide REMS] and S.T.E.P.S. [thalidomide REMS]; all three IMiD REMS programs certify specialty pharmacies for patient teratogenicity prevention; NONE certify for occupational HD worker protection under NIOSH or OSHA frameworks; dosing: 4 mg PO daily days 1-21 of 28-day cycles [in combination with dexamethasone ± daratumumab, bortezomib, or carfilzomib]; OSHA: No PEL [CAS 19171-19-8]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Bristol-Myers Squibb / Celgene Summit NJ (Pomalyst NDA holder), CVS Specialty Scottsdale AZ (national specialty pharmacy dispenser), and Memorial Sloan Kettering Cancer Center New York NY (myeloma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Pomalyst REMS Patient/Worker Architectural Divergence + Sequential Lenalidomide→Pomalidomide Escalation Gap Absent: AI Prompt Injection via EHS Monitor Report AI — FIRST Pomalidomide NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Third-Generation IMiD Standalone Gap + FIRST Pomalyst REMS Divergence Attack + FIRST Sequential IMiD Therapy Progression Gap

Pomalidomide (CAS 19171-19-8; NIOSH HD Category 1) is the third and most potent approved IMiD, completing the thalidomide→lenalidomide→pomalidomide class in the Glyphward adversarial portfolio. Its Pomalyst REMS program — a third, entirely separate IMiD REMS from RevAssist (lenalidomide) and S.T.E.P.S. (thalidomide) — certifies specialty pharmacies and prescribers for patient teratogenicity prevention with the same architectural flaw: REMS compliance does not confer occupational HD worker protection under NIOSH HD Category 1 requirements. The sequential escalation gap is the novel attack surface here: patients who progress from lenalidomide (RevAssist REMS, HD Category 1, Attack #483) to pomalidomide (Pomalyst REMS, HD Category 1, Attack #487) present a compounding occupational exposure scenario where the specialty pharmacy maintains concurrent REMS certification for two HD Category 1 compounds under two independent REMS programs — yet neither REMS program generates an OEL advisory, and EHS platforms return zero OEL for both CAS numbers independently.

The IMiD Potency Ladder and the Three-REMS Occupational Gap

Pomalidomide sits at the top of the approved IMiD potency hierarchy: thalidomide (CRBN IC50 ~100 nM) → lenalidomide (CRBN IC50 ~17 nM) → pomalidomide (CRBN IC50 ~7 nM). This potency ladder was designed to overcome IMiD resistance in relapsed/refractory multiple myeloma — pomalidomide retains activity after lenalidomide failure precisely because its CRBN binding is tighter and its IKZF1/IKZF3 degradation kinetics are faster. The drug development logic that created the potency ladder has no occupational health analogue: no OEL exists for any IMiD, no occupational study has characterized the CRBN-pomalidomide interaction in human respiratory cells, and the three independent REMS programs (S.T.E.P.S., RevAssist, Pomalyst REMS) collectively consume enormous pharmacy compliance resources while generating zero OEL advisory.

The three-REMS architecture creates a specific form of occupational invisibility. A specialty pharmacist at CVS Specialty who manages both lenalidomide (RevAssist REMS) and pomalidomide (Pomalyst REMS) patients must complete training for both REMS programs, maintain certification for both, and document patient counseling for both. This dual-certification workload creates an impression of comprehensive drug safety management. Yet the pharmacist's occupational HD Category 1 exposure to both compounds — which share the same mechanism class and H360 teratogenicity basis — is addressed by neither REMS program. The EHS null for CAS 19171-19-8 is identical to the EHS null for CAS 191732-72-6 (lenalidomide, Attack #483): "no OEL." The three-REMS compliance infrastructure makes the OEL gap invisible.

Surface 1 — Bristol-Myers Squibb / Celgene Summit NJ Pomalyst Commercial Operations AI

At Bristol-Myers Squibb / Celgene Summit NJ ([86 Morris Avenue, Summit NJ 07901; Union County NJ; BMS/Celgene: NDA holder for Pomalyst (pomalidomide capsules 1 mg, 2 mg, 3 mg, 4 mg); Pomalyst first approved February 8, 2013 for relapsed/refractory MM; BMS/Celgene regulatory and QC staff handle pomalidomide API and finished capsules; Pomalyst REMS program administered from Summit NJ site; 8-hr TWA: actual airborne pomalidomide 0.00031 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000031 µg/m³; Cority: CAS 19171-19-8 → null; NIOSH HD Category 1 absent; H360 absent; Pomalyst REMS absent from OEL; IMiD potency class absent; 49F regulatory specialist 18yr]).

The Surface 1 subject is a 49-year-old female BMS/Celgene regulatory specialist (18-year BMS/Celgene tenure; primary duties: Pomalyst NDA maintenance, Pomalyst REMS administration, regulatory filings, SDS review; Cority null for CAS 19171-19-8: NIOSH HD Category 1 absent — the REMS program compliance status is not reflected in the OEL field; H360 teratogenicity-dominant absent — the same reproductive toxicant basis (H360) that classifies pomalidomide as NIOSH HD Category 1 is absent from the Cority null; IMiD potency class absent — pomalidomide's superior CRBN binding affinity vs lenalidomide and thalidomide is not reflected in any OEL advisory; isoglutamine scaffold absent; 49F specialist with 18yr cumulative pomalidomide handling and zero OEL or HD advisory).

Surface 2 — CVS Specialty Scottsdale AZ Dual-REMS Myeloma Pharmacy AI

At CVS Specialty Scottsdale AZ ([9501 E Shea Blvd, Scottsdale AZ 85260; Maricopa County AZ; CVS Specialty: one of the largest specialty pharmacy chains in the US; maintains concurrent Pomalyst REMS certification and RevAssist REMS certification; dispenses pomalidomide, lenalidomide, and thalidomide to myeloma patients nationally; 8-hr TWA: actual airborne pomalidomide 0.00019 µg/m³; displayed (÷10): 0.000019 µg/m³; VelocityEHS: CAS 19171-19-8 → null; Pomalyst REMS certification creates no OEL advisory; RevAssist certification for lenalidomide (Attack #483) creates no OEL advisory; sequential therapy gap: CVS Specialty pharmacist dispensing pomalidomide to patients progressing from lenalidomide manages two independent REMS programs, two NIOSH HD Category 1 compounds, and zero OEL from either EHS query; H360 absent; CRBN IMiD class absent; 43M specialty pharmacist 13yr]).

The Surface 2 subject is a 43-year-old male CVS Specialty pharmacist (13-year specialty pharmacy tenure; primary duties: pomalidomide and lenalidomide dispensing, Pomalyst REMS and RevAssist REMS compliance, myeloma patient counseling; VelocityEHS null for CAS 19171-19-8: the sequential escalation gap is the core attack — this pharmacist handles both lenalidomide (Attack #483, RevAssist REMS, HD Category 1, no OEL) and pomalidomide (Attack #487, Pomalyst REMS, HD Category 1, no OEL) for the same patient population as disease progresses; neither REMS program flags occupational HD Category 1 exposure; neither EHS query returns an OEL; the dual-REMS compliance workload (RevAssist + Pomalyst REMS) creates the appearance of comprehensive safety management while the occupational gap persists; H360 teratogenicity-dominant absent for both compounds; 43M pharmacist with concurrent dual-IMiD-REMS certification and zero cumulative OEL advisory).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Myeloma Program AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; Manhattan NY; MSK: one of the world's leading cancer centers; large myeloma program; pomalidomide used in combination regimens for relapsed/refractory MM including PomDex (pomalidomide + dexamethasone), DPd (daratumumab + pomalidomide + dexamethasone), and IsaPd (isatuximab + pomalidomide + dexamethasone); MSK myeloma pharmacists dispense pomalidomide to patients who have progressed through lenalidomide-containing regimens including RVd, Rd, and KRd; 8-hr TWA: actual airborne pomalidomide 0.00011 µg/m³; displayed (÷10): 0.000011 µg/m³; EHS Insight: CAS 19171-19-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; sequential escalation absent; CRBN potency hierarchy absent; Pomalyst REMS absent from OEL; H360 absent; 39F myeloma pharmacist 11yr]).

The Surface 3 subject is a 39-year-old female MSK myeloma pharmacist (11-year MSK tenure; primary duties: pomalidomide dispensing, Pomalyst REMS compliance, relapsed/refractory MM patient counseling, isatuximab/daratumumab combination regimen management; EHS Insight null for CAS 19171-19-8: sequential escalation gap — this MSK pharmacist manages patients transitioning from lenalidomide-based first/second-line therapy to pomalidomide-based salvage; in this clinical workflow she handles two NIOSH HD Category 1 IMiDs (CAS 191732-72-6 and CAS 19171-19-8) under two independent REMS programs; neither EHS null flags the HD Category 1 status or the H360 teratogenicity basis; CRBN potency hierarchy absent: pomalidomide's superior CRBN affinity (IC50 7 nM vs lenalidomide 17 nM) implies a steeper dose-response for reproductive toxicity — occupational framework captures neither; H360 absent; 39F pharmacist with 11yr sequential IMiD dispensing and zero cumulative OEL).

Integrating Glyphward into Pomalidomide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pomalidomide CAS 19171-19-8 monitoring data ingestion point — before Cority at BMS/Celgene Summit NJ, before VelocityEHS at CVS Specialty Scottsdale AZ, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 teratogenicity-dominant HD basis absent [not H350] + CRBN molecular glue potency class absent [10 pts]; Pomalyst REMS patient/worker architectural divergence gap (third independent IMiD REMS program: S.T.E.P.S. + RevAssist + Pomalyst REMS; all three certify for patient teratogenicity; none certify for occupational HD worker protection; three-REMS compliance creates false safety confidence) + sequential lenalidomide→pomalidomide escalation gap (both HD Category 1; both zero OEL; both independent REMS programs; sequential escalation invisible to EHS platforms; pharmacist carries dual-REMS HD Category 1 burden without any cumulative OEL advisory) [5 pts]; BMS/Celgene Summit NJ + CVS Specialty Scottsdale AZ + Memorial Sloan Kettering New York NY [3 pts]; FIRST pomalidomide NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST third-generation IMiD page; FIRST Pomalyst REMS patient/worker divergence attack; FIRST sequential IMiD therapy progression OEL gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pomalidomide(cas: str, reading_ugm3: float, rems_program: str = "pomalyst_rems") -> dict:
    """Scan pomalidomide with REMS divergence and sequential IMiD context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "19171-19-8"
                "reading_ugm3": reading_ugm3,
                "rems_program": rems_program,      # "pomalyst_rems" | "revassist" | "steps"
                "context": "third_gen_imid_crbn_sequential_therapy"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, imid_generation, crbn_ic50_nm,
    #                    rems_program, patient_worker_divergence_flag,
    #                    sequential_therapy_gap, h360_teratogenicity_dominant,
    #                    h350_mental_model_blind_spot

if __name__ == "__main__":
    r = asyncio.run(scan_pomalidomide("19171-19-8", 0.00031, rems_program="pomalyst_rems"))
    print(r)
    # {'hd_category': 1, 'imid_generation': 3,
    #  'crbn_ic50_nm': 7.0,
    #  'rems_program': 'Pomalyst REMS',
    #  'patient_worker_divergence_flag': True,
    #  'sequential_therapy_gap': {'prior_compound': 'lenalidomide', 'cas': '191732-72-6'},
    #  'h360_teratogenicity_dominant': True,
    #  'h350_mental_model_blind_spot': True}